<DOC>
	<DOCNO>NCT00116779</DOCNO>
	<brief_summary>The purpose study contribute , along dose-finding study , identification effective treatment regimen one month depot injection degarelix treatment prostate cancer rapid sustain suppression testosterone .</brief_summary>
	<brief_title>A Parallel Group Comparison Efficacy Safety Degarelix Two Different Dosing Regimens Patients With Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Each patient must meet follow inclusion criterion entry study . Has give write consent prior studyrelated activity perform ( studyrelated activity define procedure would perform normal management patient ) . Histologically confirm adenocarcinoma prostate ( stage ) , endocrine treatment ( except neoadjuvant hormonal therapy ) indicate . This include patient rise PSA receive radical prostatectomy ( removal entire prostate seminal vesicle ) radiotherapy curative intention . Male patient age 18 year . Has baseline testosterone low limit normal range . Has ECOG ( Eastern Cooperative Oncology Group ) score equal less 2 . Has PSA value great equal 2ng/mL . Any patient meeting one follow exclusion criterion enter study . Previous present hormonal management prostate cancer ( surgical castration hormonal manipulation , e.g . GnRH agonist , GnRH antagonists , antiandrogens , estrogen ) . However , patient undergo neoadjuvant hormonal therapy conjunction prostatectomy radiotherapy curative intention may include long hormonal therapy exceed total duration 6 month terminate least 6 month prior Screening Visit . Currently recently ( within last 12 week precede Screening Visit ) treatment drug modify testosterone level function . Is consider candidate curative therapy , i.e. , radical prostatectomy radiotherapy within 6 month Screening Visit . Has history severe asthma ( defined need daily treatment oral inhalation steroid control asthma ) , anaphylactic reaction , angioedema , angioneurotic edema Quincke 's Edema . Has hypersensitivity towards component investigational product ( degarelix mannitol ) . Has history cancer within last 5 year except prostate cancer surgically remove basal squamous cell carcinoma skin . Has elevate serum ALT level three time upper level normal range serum total bilirubin level one half time upper level normal range measure laboratory Screening Visit . Has know suspect hepatic disease sort . Patients liver disease enrol study . Has clinically significant laboratory abnormality , judgment investigator would interfere participation patient study evaluation study result . Has clinically significant disorder ( prostate cancer ) condition , include excessive alcohol drug abuse , may interfere trial participation may affect conclusion study judge investigator . Has mental incapacity language barrier preclude adequate understanding cooperation . Has receive investigational drug within last 12 week precede Screening Visit . Has previously participate degarelix study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Androgen ablation therapy</keyword>
</DOC>